Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)

SUZHOU, China and SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ — Eluminex Biosciences today announced the completion of clinical enrollment in Part A (N=5) of a two-part pivotal study (CLARITY) evaluating a novel EB-301 biosynthetic cornea being conducted in China. The EB-301 investigational corneal implant is manufactured from recombinant human Type III collagen (rhCIII) and is intended to treat corneal blindness secondary to stromal lesions amenable to anterior lamellar keratoplasty (ALK) surgery.

Michael Bond

Michael Bond

Leave a Reply

Your email address will not be published. Required fields are marked *